Australia is closely watching the arrival of retatrutide, a innovative dual GIP and GLP-1 receptor medication , representing a potential advance in obesity treatment . Early clinical trials have demonstrated https://theosdbd142156.jaiblogs.com/70899235/emerging-medication-in-australia-a-promising-breakthrough-for-obesity-management